Home › Forums › Main Forum › FixHepC Admin › Sofosvel (velpatasvir)
- This topic has 92 replies, 25 voices, and was last updated 7 years, 11 months ago by vitrus.
-
AuthorPosts
-
27 July 2016 at 3:35 pm #2147827 July 2016 at 5:37 pm #21485
I’ll second that Yahoo Tweakmax. Way to go Beacon Pharma!
27 July 2016 at 7:09 pm #21488This is fantastic news! Hats off to Beacon!!!
27 July 2016 at 11:20 pm #21494I tried to go to the main company website and it said that the account was suspended and to contact my hosting provider.
http://www.beacon-pharma.com
G4
F0-F1
diagnosed in 2006
Tx naive
Treatment started 8/12/16, Ledipasvir/ Sofosbuvir (Harvoni) supplied by Monkmed
8/1/16 ALT 36 AST 40
1/4/17 ALT 17 AST 21
7/13/17 ALT 17 AST 25
12/28/17 ALT 22 AST26
2/22/18 ALT 19 AST 25
7/10/18 ALT 26 AST 32
1/8/19 ALT 16 AST 28
7/2/19 ALT 16 AST 26
Hcv Rna, Quantitative Real Time Pcr <15 NOT DETECTED (IU/mL) NOT DETECTED27 July 2016 at 11:29 pm #21497Hi Beahaven,
same remark from my side, I believe in between the webpage changed and it needs to be updated also on this forum.
See my post from some minutes ago.Cheers,
RHF
In fiecare an HCV ucide peste 500000 oameni.Medicamentele generice pentru hepatita C functioneaza. Nu deveni statistica! Cauta pe Google “medicamente generice pentru hepatita C”.
HCV kills more than 500000 people every year. HCV generic drugs work. Don’t become a statistic.
By sharing this Youtube video you might save someone’s life!
My TX: HEPCVIR-L[generic Harvoni]-India
SVR52 achieved28 July 2016 at 12:06 am #21499UPDATE: July 27th 2016
As per the current timelines GILEAD Licensed Velpatasvir will be available in early September 2016 in India. Epclusa( GILEAD Velpatasvir) is already licensed to Gilead’s 11 Indian manufacturing partners which includes top brands like Mylan,Cipla & Natco which have undergone a complete transfer of technology(TOT). https://en.wikipedia.org/wiki/Technology_transfer.
Licensing does not mean just a business aspect of royalty sharing but more importantly ensuring the quality of the licensed product is exactly same as that of the original pill. This aspect is ensured by rigorous TOT which is explained below.
A complete technology of transfer(TOT) means the process of manufacturing of the pills is exact same as of the original GILEAD pill not just limited to the API but aspects of Excipient which is the NON API materials that goes into the manufacturing https://en.wikipedia.org/wiki/Excipient.
On top of the above, premium companies like Cipla and Mylan have their own Quality assurance processes. So even if pills are manufactured by Hetero and Hetero has its own Quality Assurance and Testing of the pills, after they hand over the pills Cipla and Mylan have their own comprehensive Quality Assurance and Testing process . We like this aspect of double testing which is the precise reason doctors world over trust Cipla and Mylan.
Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.https://en.wikipedia.org/wiki/Mylan.
On top of all the above all Indian manufacturing units that manufacture or sell Licensed products are US FDA certified and have to keep up with rigorous standards also called Current Good Manufacturing Practices (CGMPs)
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm
Currently DCGI (Drug Controller General of India) approval for generic Velpatasvir is in process as the 11 Indian companies are gearing up production for early September launch.
28 July 2016 at 2:02 am #21508rohcvfighter wrote:Hi Beahaven,
same remark from my side, I believe in between the webpage changed and it needs to be updated also on this forum.
See my post from some minutes ago.Cheers,
RHFBeacon’s Pharmas Market page has been updated to their new web address: http://www.beaconpharma.com.bd
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
28 July 2016 at 3:12 am #21511Ha ha, that didn’t take long 3 cheers for Bangladesh (exempt from pharmaceutical patents until 2033)
I’m sure Gilead are thrilled!
Already taking orders
28 July 2016 at 5:23 am #21513
Genotype 3
VL 4,100,000
ALT 101 AST 71
Treatment Naive
Started Sof/Dac Jan 12, 2016
VL= <15 4 weeks in. AST/ALT normal.
VL=UNDETECTED 8 weeks in.
SVR4= Virus back. 3,300,000Started generic Epclusa Sep. 23, 2017
4 weeks in <15 *Detected.
12 weeks in <15 *Not Detected.
16 weeks in <15 *Not Detected.
Finished 24 weeks treatment 3-17-18
SVR5 <15 Not Detected.
SVR 20 <15 Not Detected.
SVR 44 <15 Not Detected.Thank you Jesus.
Thank you Dr. James28 July 2016 at 11:06 am #21532Left to right: Md Monjur Alam, Md. Ebadul Karim (Managing Director), Dr James Freeman, Prof. Dr. Syed Modasser Ali (Chaiman of BMRC), and Mr James Cheng
YMMV
28 July 2016 at 11:27 am #21537
Sofosvel is the 3rd product we launched as first global generic from beacon pharmaceuticals Ltd. Today is the world hepatitis day and launching of the Sofosvel (sofosbuvir + velpatasvir) is the great news for all hep c patients. They can get right treatment at affordable price. Our earlier two global first generic products were Tagrix (osimertinib) for lung cancer & Darvoni (sofosbuvir + daclatasvir) for all genotypes of hepatitis patients.Attachments:28 July 2016 at 11:34 am #2154028 July 2016 at 12:16 pm #21541Pharma’s Market updated.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
28 July 2016 at 4:33 pm #21543Outstanding!
Some people just talk about doing things. Others make them happen.
Thank you Beacon, and Dr James Freeman!
Also, whoever did the branding/graphics is brilliant. GREAT professional branding!
29 July 2016 at 4:53 pm #21622 -
AuthorPosts
- You must be logged in to reply to this topic.